Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) has been assigned a consensus rating of "Hold" from the five brokerages that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $13.75.

A number of research analysts have recently issued reports on the stock. Leerink Partnrs cut shares of Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 6th. TD Cowen dropped their target price on Theravance Biopharma from $10.00 to $9.00 and set a "hold" rating on the stock in a report on Tuesday, August 6th. Leerink Partners cut Theravance Biopharma from an "outperform" rating to a "market perform" rating and cut their target price for the company from $15.00 to $10.00 in a research report on Tuesday, August 6th. StockNews.com lowered Theravance Biopharma from a "buy" rating to a "hold" rating in a research report on Saturday, August 10th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Theravance Biopharma in a report on Monday, September 16th.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now owns 322,743 shares in the company, valued at approximately $2,904,687. This represents a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 6.90% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. PDT Partners LLC raised its holdings in shares of Theravance Biopharma by 31.2% in the 3rd quarter. PDT Partners LLC now owns 87,177 shares of the biopharmaceutical company's stock worth $703,000 after purchasing an additional 20,738 shares during the period. Martingale Asset Management L P increased its position in Theravance Biopharma by 14.4% in the third quarter. Martingale Asset Management L P now owns 54,450 shares of the biopharmaceutical company's stock worth $439,000 after buying an additional 6,870 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Theravance Biopharma by 29.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,978 shares of the biopharmaceutical company's stock valued at $137,000 after buying an additional 3,827 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Theravance Biopharma by 88.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company's stock valued at $2,462,000 after buying an additional 143,781 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Theravance Biopharma during the 3rd quarter worth $60,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Price Performance

Shares of TBPH traded down $0.11 during trading hours on Thursday, hitting $9.57. The stock had a trading volume of 256,679 shares, compared to its average volume of 345,944. The firm has a 50 day simple moving average of $8.36 and a 200-day simple moving average of $8.69. Theravance Biopharma has a 1-year low of $7.44 and a 1-year high of $11.71. The firm has a market capitalization of $468.18 million, a P/E ratio of -9.58 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. The firm had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. During the same quarter in the prior year, the firm earned ($0.17) EPS. Equities analysts predict that Theravance Biopharma will post -1.04 EPS for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.